Guanabenz

For research use only. Not for therapeutic Use.

  • CAT Number: M004877
  • CAS Number: 5051-62-7
  • Molecular Formula: C8H8Cl2N4
  • Molecular Weight: 231.08
  • Purity: ≥95%
Inquiry Now

Guanabenz(Cat No.:M004877)is an alpha-2 adrenergic receptor agonist primarily used as an antihypertensive agent to treat high blood pressure. By stimulating alpha-2 receptors in the central nervous system, it reduces sympathetic nervous system activity, leading to a decrease in heart rate and blood vessel constriction, which lowers blood pressure. In addition to its antihypertensive effects, Guanabenz has shown potential neuroprotective properties, making it of interest in research for neurodegenerative diseases such as multiple sclerosis. Its central mode of action makes it a valuable option for managing hypertension.


Catalog Number M004877
CAS Number 5051-62-7
Synonyms

GUANABENZ;1-(2,6-DICHLOROBENZYLIDENEAMINO)GUANIDINE;2-[(2,6-dichlorophenyl)methylene]-hydrazinecarboximidamide;n-(2,6-dichlorobenzylidene)amino]guanidine;n-(2,6-dichlorobenzylidene)-n’-amidinohydrazine;nsc-68982;Rexitene;HydrazinecarboxiMidaMide, 2-[

Molecular Formula C8H8Cl2N4
Purity ≥95%
Target Neuronal Signaling
Storage -20°C
IUPAC Name 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
InChI InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
InChIKey WDZVGELJXXEGPV-YIXHJXPBSA-N
SMILES C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
Reference

1: Neuber C, Uebeler J, Schulze T, Sotoud H, El-Armouche A, Eschenhagen T.
Guanabenz interferes with ER stress and exerts protective effects in cardiac
myocytes. PLoS One. 2014 Jun 3;9(6):e98893. doi: 10.1371/journal.pone.0098893.
eCollection 2014. PubMed PMID: 24892553; PubMed Central PMCID: PMC4044035.
<br>

2: Takigawa S, Chen A, Nishimura A, Liu S, Li BY, Sudo A, Yokota H, Hamamura K.
Guanabenz Downregulates Inflammatory Responses via eIF2α Dependent and
Independent Signaling. Int J Mol Sci. 2016 May 5;17(5). pii: E674. doi:
10.3390/ijms17050674. PubMed PMID: 27164082; PubMed Central PMCID: PMC4881500.
<br>

3: Wang L, Popko B, Tixier E, Roos RP. Guanabenz, which enhances the unfolded
protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis.
Neurobiol Dis. 2014 Nov;71:317-24. doi: 10.1016/j.nbd.2014.08.010. Epub 2014 Aug
15. PubMed PMID: 25134731; PubMed Central PMCID: PMC4179984.
<br>

4: Osborn MF, Alterman JF, Nikan M, Cao H, Didiot MC, Hassler MR, Coles AH,
Khvorova A. Guanabenz (Wytensin&#8482;) selectively enhances uptake and efficacy of
hydrophobically modified siRNAs. Nucleic Acids Res. 2015 Oct 15;43(18):8664-72.
doi: 10.1093/nar/gkv942. Epub 2015 Sep 22. PubMed PMID: 26400165; PubMed Central
PMCID: PMC4605330.

<br>
5: Jiang HQ, Ren M, Jiang HZ, Wang J, Zhang J, Yin X, Wang SY, Qi Y, Wang XD,
Feng HL. Guanabenz delays the onset of disease symptoms, extends lifespan,
improves motor performance and attenuates motor neuron loss in the SOD1 G93A
mouse model of amyotrophic lateral sclerosis. Neuroscience. 2014 Sep
26;277:132-8. doi: 10.1016/j.neuroscience.2014.03.047. Epub 2014 Mar 31. PubMed
PMID: 24699224.

<br>
6: Benmerzouga I, Checkley LA, Ferdig MT, Arrizabalaga G, Wek RC, Sullivan WJ Jr.
Guanabenz repurposed as an antiparasitic with activity against acute and latent
toxoplasmosis. Antimicrob Agents Chemother. 2015 Nov;59(11):6939-45. doi:
10.1128/AAC.01683-15. Epub 2015 Aug 24. PubMed PMID: 26303803; PubMed Central
PMCID: PMC4604420.

Request a Quote